Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Though Eli Lilly stock looks quite expensive ... announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring ...

ByInvesting.com • Aug 20, 2024 Eli Lilly stock soars to all-time high of $967 amid robust growth Eli Lilly and Co's stock has reached an unprecedented peak, touching an all-time high of $967.

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker ... slowdown to a lower-than-expected amount of the drugs in stock at the end of the year and changes to Medicare Part ...

Eli Lilly stock rises on upbeat guidance, and Ford Motor’s operating profit forecast disappoints. Honeywell, meanwhile, announces a plan to break up into three companies. Shares of semiconductor ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...